Filing identity and reporting period
Important discrepancy: The supplied filing is NeoStem, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed March 20, 2012. It is not identified in the filing as a Lisata Therapeutics, Inc. filing or a 2010 Q4 report. The summary below reflects the supplied NeoStem filing.
Business context
NeoStem operated three reportable segments: U.S. Cell Therapy, China Regenerative Medicine, and China Pharmaceutical Manufacturing. The company was shifting its strategy toward cell therapy following its 2011 acquisitions of Progenitor Cell Therapy (PCT) and Amorcyte. PCT provides cell-therapy manufacturing and development services; Amorcyte’s lead candidate, AMR-001, was being developed for cardiovascular disease. NeoStem said it planned to restrict and ultimately exit its China regenerative-medicine operations and was pursuing strategic alternatives for its 51% stake in Erye, a Chinese pharmaceutical manufacturer.
Financial results and liquidity
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $73.7 million | $69.8 million |
| Gross profit / gross margin | $17.7 million / 24.1% | $20.2 million / 28.9% |
| Operating loss | $54.5 million | $18.9 million |
| Net loss | $56.6 million | $19.4 million |
| Net loss attributable to common shareholders | $47.8 million | $23.5 million |
| Net loss per share, basic and diluted | $0.54 | $0.46 |
| Cash used in operating activities | $20.9 million | $8.5 million |
| Cash and cash equivalents at year-end | $12.7 million | $15.6 million |
| Working capital at year-end | $2.2 million | Not stated here |
- Revenue mix: Erye generated $63.4 million, down about 9%; U.S. Cell Therapy generated $10.1 million, primarily from PCT, acquired in January 2011; China Regenerative Medicine generated $0.3 million.
- Expenses and unusual items: Operating expenses rose 85% to $72.3 million. R&D was $11.0 million, up 43%, and SG&A was $41.8 million, up 36%. The company recorded a $19.4 million goodwill impairment in the China pharmaceutical segment, citing lower-than-expected revenue and operating-income growth.
- Debt and other obligations: Year-end current bank loans were $15.7 million, mortgages payable were $3.6 million, and amounts due to related parties were $20.9 million. The company also had Series E preferred stock subject to mandatory redemption and 7% dividends. PCT was not in compliance with mortgage financial covenants at year-end but obtained lender waivers through December 31, 2011.
- Cash availability: $8.8 million of cash and short-term investments held by foreign subsidiaries was not available for domestic operations unless repatriated. Separately, $2.5 million was held in escrow for Series E obligations, and approximately $2.46 million of Erye cash was frozen in litigation-related proceedings.
Material changes versus FY 2010
- Total revenue increased about 6%, but gross profit declined about 12% and gross margin fell by approximately 4.8 percentage points.
- U.S. Cell Therapy revenue increased following the PCT acquisition; reported comparisons include only post-acquisition results. The filing also provides unaudited pro forma figures assuming both PCT and Amorcyte had been acquired at the start of each year.
- Operating loss and net loss increased substantially, reflecting higher operating costs, acquisitions, and the China-segment goodwill impairment. The filing reports $47.8 million of 2011 loss attributable to common shareholders versus $23.5 million in 2010.
- Operating cash outflow increased to $20.9 million from $8.5 million. Financing provided $20.1 million, mainly through equity financing and China bank borrowing; cash declined by $2.9 million during 2011.
- Erye revenue fell, and the company cited lower sales volumes, product-mix changes, pricing pressure, and currency effects. Erye reported a fourth-quarter net loss, but the filing text does not provide a clear amount.
Outlook, risks and contingencies
- Clinical outlook: NeoStem began enrolling patients in January 2012 in the planned 160-patient PreSERVE Phase 2 AMR-001 trial. Management expected enrollment to take about a year, with an initial data readout in the second half of 2013. The trial was estimated to cost approximately $14 million over its first two years and up to $18 million over five years. The company also expected to begin an AMR-001 Phase 1 trial for congestive heart failure by 2013 and said it expected a VSEL safety trial by 2013.
- China strategy: The company anticipated exiting the majority of its China operations by the end of 2012, but Erye sale discussions had produced only nonbinding letters of intent. A sale was uncertain, subject to EET’s right of first refusal and Chinese regulatory, tax, financing, and operating issues; management expected any sale might not recoup the original investment.
- Funding and dilution: Management anticipated needing substantial additional capital to fund clinical development and operations. NeoStem raised about $21.2 million through common-stock and warrant offerings in 2011 and $2.25 million in a February 2012 private placement. It also had an agreement allowing, subject to conditions, up to $20 million of stock sales to Aspire Capital. Further equity financing could dilute existing holders; available funding and terms were uncertain.
- Regulatory and clinical risks: AMR-001 remained investigational, and Phase 2 and later-stage success, FDA approval, manufacturing controls, patient enrollment, and commercial acceptance were uncertain. In the Phase 1 trial, one participant died after ventricular fibrillation attributed to recurrent heart attack from stent thrombosis before infusion; the event led to a clinical hold that was later lifted after FDA review and enrollment-procedure changes.
- China and legal exposures: China announced a halt to unapproved stem-cell trials and suspended new applications through July 1, 2012, prompting the planned wind-down of regenerative-medicine activities. Erye faced ongoing copyright-infringement litigation; $2.46 million of its cash was frozen. Potential Chinese tax liabilities and penalties tied to correcting ownership-related regulatory filings could not be reasonably assessed at year-end.
- Financial reporting controls: Management identified a material weakness at Erye due to insufficient qualified accounting and finance personnel, including inadequate segregation of duties and records. Management concluded that internal control over financial reporting and disclosure controls were not effective at year-end. The independent auditor audited the financial statements but did not opine on internal-control effectiveness.
- Other unusual matters: The company reversed a previously accrued approximately $0.78 million patent-infringement judgment after a favorable subsequent ruling. It also disclosed related-party transactions, including a $3.0 million payment to a credit line lender associated with a PCT executive and a $0.61 million stock contribution to a foundation whose officers included company executives.
Important facts for investors to verify
- Confirm the filing’s identity and period: NeoStem FY 2011, not Lisata Therapeutics or 2010 Q4.
- Review the cash runway, near-term financing needs, preferred-stock redemption schedule, debt terms, and the availability of offshore and restricted cash.
- Track AMR-001 Phase 2 enrollment, trial spending, safety updates, and the timing and interpretation of clinical readouts.
- Verify whether Erye is divested, what proceeds are realized, and whether Chinese regulatory, ownership, tax, or litigation issues affect the transaction or cash flows.
- Monitor Erye’s pricing and antibiotic-volume exposure, operating performance, frozen cash, and the status of its accounting-control remediation.
- Assess dilution from outstanding options and warrants, preferred-stock conversions or redemptions, and potential Aspire Capital stock sales.